EUVIMEDOdkrijte EUVIMED
Klinische Studie (Phase I)Open access · CC BY-NC-ND 4.0

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Thomas E Kraft iD, Estelle Marrer-Berger iD, Sara Belli iD, Helene Haegel iD, Anneliese Schneider iD, Anna Maria Giusti iD, Michael Bscheider iD, Wolfgang Jacob iD, Martin Weisser, Laura Blanco iD, Nicolas Frances, Eva Rossmann iD and 5 more

Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 745-752

DOI: 10.1002/cpt.70366 ↗

At a glance

Klinische Studie (Phase I) in Clinical Pharmacology & Therapeutics, published online on 2026-06-17. Written by Thomas E Kraft and 16 co-authors. Institution: Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany. Major MEDLINE topics: Multiple Myeloma, T-Lymphocytes, Antibodies, Bispecific. 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed/refractory multiple myeloma (RRMM). We used in vitro and ex vivo MABEL approaches to calculate the FIH dose for a Phase 1 trial (NCT04557150) in patients with RRMM. In vitro assays used the OPM‐2 MM cell line and peripheral blood mononucleocytes from healthy donors and patients with MM. Ex vivo assays used fresh bone marrow aspirates from MM patient donors. Forimtamig increased tumor cell lysis, cytokine release, and T‐cell activation in vitro and ex vivo . Tumor cell lysis was considered the most relevant assay for dose calculation. EC 50 for LDH release ( in vitro : mean 0.6 pM; ex vivo : 9 pM for the most sensitive patient) led to calculated FIH starting doses of 0.4 and 6 μg, respectively. FIH starting dose was 6 μg. Clinical activity was observed in the second dosing cohort (18 and 54 μg). The third dosing cohort (54 and 162 μg) showed durable objective responses. Cytokine release syndrome was Grade 1 at the starting dose and absent in the second dosing cohort. Our ex vivo MABEL approach was accepted by regulatory authorities and yielded a tolerated forimtamig FIH starting dose which demonstrated clinical activity in the second dosing cohort. We encourage similar innovative patient‐centric approaches to FIH dose calculation.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaT-LymphocytesAntibodies, BispecificHumansDose-Response Relationship, DrugCell Line, TumorFemaleMaleMiddle AgedAntibodies, Monoclonal, Humanized

Substances

Antibodies, Bispecificbelantamab mafodotinAntibodies, Monoclonal, Humanized

Authors and institutions

  • Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Cancer Center Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, University of Navarra, IDISNA, CIBERONC, Pamplona, Spain.
  • Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Toulouse III-Paul Sabatier (UPS), Toulouse,…

ORCID profiles: Thomas E Kraft, Estelle Marrer-Berger, Sara Belli, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Michael Bscheider, Wolfgang Jacob, Laura Blanco, Eva Rossmann, Aintzane Zabaleta Azpiroz, Bruno Paiva, Tanja Fauti

Cite

APA

Kraft, T. E., Marrer-Berger, E., Belli, S., Haegel, H., Schneider, A., Giusti, A. M., Bscheider, M., Jacob, W., Weisser, M., Blanco, L., Frances, N., Rossmann, E., Steiner, G., Azpiroz, A. Z., Paiva, B., Martinet, L., & Fauti, T. (2026). Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma. Clinical Pharmacology & Therapeutics, 120(3), 745-752. https://doi.org/10.1002/cpt.70366

Vancouver

Kraft TE, Marrer-Berger E, Belli S, Haegel H, Schneider A, Giusti AM, et al. Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma. Clinical Pharmacology & Therapeutics. 2026;120(3):745-752. doi:10.1002/cpt.70366

BibTeX
@article{Kraft2026,
  author = {Kraft, Thomas E and Marrer-Berger, Estelle and Belli, Sara and Haegel, Helene and Schneider, Anneliese and Giusti, Anna Maria and Bscheider, Michael and Jacob, Wolfgang and Weisser, Martin and Blanco, Laura and Frances, Nicolas and Rossmann, Eva and Steiner, Guido and Azpiroz, Aintzane Zabaleta and Paiva, Bruno and Martinet, Ludovic and Fauti, Tanja},
  title = {Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {3},
  pages = {745--752},
  doi = {10.1002/cpt.70366}
}
Start for free →